Kazia Therapeutics Limited
KZIA
$13.16
-$0.67-4.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.24% | -98.24% | -98.24% | 1.95% | -- |
| Total Other Revenue | 816.08% | 852.31% | 895.17% | 993.18% | 21,350.00% |
| Total Revenue | -26.84% | -27.91% | -28.97% | 71.43% | 274,583.33% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -26.84% | -27.91% | -28.97% | 71.43% | 274,583.33% |
| SG&A Expenses | -15.13% | -25.99% | -36.38% | 1.36% | 58.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.81% | -43.04% | -48.71% | -6.07% | 60.61% |
| Operating Income | 37.67% | 44.36% | 50.43% | 10.08% | -47.85% |
| Income Before Tax | 16.73% | 17.97% | 18.27% | -17.92% | -78.49% |
| Income Tax Expenses | -471.29% | -496.03% | -524.93% | -258.55% | 0.78% |
| Earnings from Continuing Operations | 21.39% | 23.01% | 23.76% | -14.84% | -79.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.39% | 23.01% | 23.76% | -14.84% | -79.86% |
| EBIT | 37.67% | 44.36% | 50.43% | 10.08% | -47.85% |
| EBITDA | 37.01% | 45.01% | 52.47% | 10.19% | -53.02% |
| EPS Basic | 73.92% | 66.85% | 60.19% | 24.17% | -27.75% |
| Normalized Basic EPS | 82.80% | 74.08% | 65.74% | 32.18% | -7.07% |
| EPS Diluted | 73.91% | 66.85% | 60.18% | 24.17% | -27.75% |
| Normalized Diluted EPS | 82.80% | 74.08% | 65.74% | 32.18% | -7.07% |
| Average Basic Shares Outstanding | 213.02% | 168.28% | 107.80% | 82.67% | 54.03% |
| Average Diluted Shares Outstanding | 214.29% | 172.92% | 115.00% | 91.89% | 64.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |